Genetically determined SLC5A2 perturbation, per standard deviation unit (SD) change of antidiabetic drug target perturbation equivalent to one SD unit (6.75 mmol/mol) of HbA1c lowering, was significantly associated with elevating the risk of BCC (OR: 2.004, 95% CI: 1.270–3.161, p = 0.0027) (Supplementary Table S23). The gene discussed is SLC5A2; the disease is skin basal cell carcinoma.